Username:
Password:
Enter your email below to subscribe to our Health & Biotech News Digest.

All News

Jan 05, 2012
David Wetherell Joins Burrill & Company Venture Capital Group as Managing Director: Douglas Lind and Joshua Zelig also added to the firm's roster
SAN FRANCISCO, January 5, 2011—Burrill & Company is pleased to announce that David Wetherell, a veteran entrepreneur and venture capitalist, has joined the Burrill Venture Capital Group as a Managing Director. Along with Wetherell, Douglas Lind, MD, joined the firm as a Managing Director Read More...
Filed Under: GBP Capital News



Nov 14, 2011
Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer
Cleveland, OH. and Gaithersburg, MD. November 14, 2011 – University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protecti Read More...
Filed Under: GBP Capital News



Aug 17, 2011
Lentigen Vector Used in Landmark Cancer Clinical Study
University of Pennsylvania Researchers used a lentiviral vector designed and manufactured by Lentigen to genetically modify "Serial Killer" T-cells to obliterate tumors in patients with Chronic Lymphocytic Leukemia . Further information on this study can be found at:   http://www.uph Read More...
Filed Under: GBP Capital News



Apr 11, 2011
MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
SAN DIEGO, April 11, 2011/PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has re Read More...
Filed Under: GBP Capital News



Feb 01, 2011
FSS Receives Full Investigational Device Exemption (IDE) Approval for its FlexStent Femoropoliteal SE Stent System
EATONTOWN, NJ - (Business Wire) - Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has received full FDA Investigational Device Exemption (IDE) approval for its FlexSt Read More...
Filed Under: GBP Capital News



Nov 15, 2010
GBP Capital and ON Capital China Announce China Collaboration
Private equity firms GBP Capital, of Greenwich, CT, and ON Capital China, of Hong Kong and Beijing, today announced a collaboration between their two firms, whereby ON Capital China will assist in introducing GBP Capital’s portfolio of life science companies, where appropriate, into Chi Read More...
Filed Under: GBP Capital News



Nov 03, 2010
Lentigen Awarded $1.2 Million By U.S. Government Under the Qualifying Therapeutic Discovery Project
Gaithersburg, MD, November 3, 2010 – Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protecti Read More...
Filed Under: GBP Capital News



Aug 17, 2010
MabVax Therapeutics Receives Small Business Innovation Research Program Award From The National Cancer Institute
San Diego, CA, August 17, 2010 -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Busines Read More...
Filed Under: Company News



Aug 10, 2010
MabVax Therapeutics Receives $1.1 Million Phase 2 Small Business Technology Transfer Program Award From The National Cancer Institute
San Diego, CA, August 10, 2010 -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the follow-on Phase 2 Read More...
Filed Under: GBP Capital News



Aug 09, 2010
Lentigen Awarded Phase II SBIR Grant for Clinical Development of TCR
  Gaithersburg , MD, August 9, 2010 – Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a N Read More...
Filed Under: Company News



64 results:

1234...7>>


© 2007 GBP Capital. All Rights Reserved. Legal | Privacy Statement | Sitemap